Paricalcitol attenuates lipopolysaccharide-induced inflammation and apoptosis in proximal tubular cells through the prostaglandin E\textsubscript{2} receptor EP4

Yu Ah Hong\textsuperscript{1}, Keum Jin Yang\textsuperscript{2}, So Young Jung\textsuperscript{2}, Yoon Kyung Chang\textsuperscript{1}, Cheol Whee Park\textsuperscript{1}, Chul Woo Yang\textsuperscript{1}, Suk Young Kim\textsuperscript{1}, Hyeon Seok Hwang\textsuperscript{1,2}

\textsuperscript{1}Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
\textsuperscript{2}Clinical Research Institute, Daejeon St. Mary’s hospital, Daejeon, Korea

Introduction

Sepsis is a severely deregulated systemic inflammatory response to infection and predisposes the development of multiple organ failure. Acute kidney injury (AKI) is a frequent complication of sepsis and remains a serious cause of mortality in critically ill patients [1]. Cytokine production and the infiltration of inflammatory cells into the kidney are observed in cases of septic AKI and trigger cellular dysfunction, detachment, and apoptotic
cell death in proximal tubules [2,3]. In addition, tubular apoptosis around inflamed lesions increases the inflammatory reaction leading to the acceleration of tissue injury [4,5]. Therefore, the prevention of inflammation and apoptosis in proximal tubule cells is critical in ameliorating the septic AKI.

Many previous studies have shown that vitamin D protects kidneys from damage in various experimental models of renal disease [6,7]. We previously demonstrated that paricalcitol has a renoprotective effect in renal ischemia reperfusion injury via the upregulation of cyclooxygenase-2 (COX-2) and prostaglandin E$_2$ (PGE$_2$) [8]. The biological actions conducted by PGE$_2$ includes binding to the receptor subtypes EP1 to EP4 [9], and the activation of EP4 signaling particularly controls the transcriptional activity of nuclear factor-kappaB (NF-$\kappa$B) [10]. EP4 signaling also activates the phosphatidylinositol 3-kinase (PI3K) pathway leading to Akt activation [11,12]. However, it remains unclear whether the protective effects of paricalcitol on proximal tubule cells in septic AKI involve the EP4-signaling pathway.

Endotoxin, as a Gram-negative bacterial lipopolysaccharide (LPS), has been widely used in establishing sepsis models for its simplicity of use and quantification [4]. Therefore, we investigated the EP4-mediated role of paricalcitol in LPS-exposed human proximal tubular epithelial (HK-2) cells. This study aimed to determine whether paricalcitol modulates the PGE$_2$–EP4-signaling pathway in HK-2 cells and the EP4-dependent pathway is critical for the anti-inflammatory and ant apoptotic effects of paricalcitol in HK-2 cells with LPS injury.

**Methods**

**Human proximal tubular cell experiments**

HK-2 cells (American Type Culture Collection, Manassas, VA, USA) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum, 50 U/mL penicillin, and 50 µg/mL streptomycin. To stimulate with LPS (Sigma-Aldrich, St. Louis, MO, USA), 80% confluent HK-2 cells were incubated with serum-free DMEM for 16 hours. HK-2 cells were pretreated with paricalcitol (19-nor-1,25-dihydroxyvitamin D$_3$, 2 ng/mL; Abbott Laboratories, Chicago, IL, USA) for 1 hour, and then exposed to LPS (1 µg/mL). Cells were harvested 24 hours after LPS exposure to assess the effects on the expression of the vitamin D receptor (VDR), COX-2, and PGE$_2$ receptor subtypes. The cells were also harvested for analysis of p65 NF-$\kappa$B phosphorylation and nuclear translocation and Akt phosphorylation 15 minutes after LPS exposure.

**Treatment of EP4 antagonist and EP4 small-interfering RNA**

The EP4 blockade was induced by AH-23848 (2 µM; Santa Cruz Biotechnology, Santa Cruz, CA, USA), an EP4-specific antagonist, or EP4 small interfering RNA (siRNA) (Bioneer Corp., Daejeon, Korea). AH-23848 (2 µM) was dissolved in NaHCO$_3$ and diluted with distilled water. AH-23848 was simultaneously pretreated with paricalcitol for 1 hour before LPS injury. siRNAs targeted to EP4 or scrambled siRNA (Bioneer Corp.) were complexed with Lipofectamine RNAiMax (Invitrogen Biotechnology, Carlsbad, CA, USA) according to the manufacturer’s instructions. HK-2 cells were transfected with EP4 siRNAs or scrambled siRNA for 24 hours. Twenty-four hours after transfection, cells were treated with paricalcitol and exposed to LPS.

**Measurement of cell viability**

A commercially available 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (EZ-Cytox; Daeil Lab Service, Seoul, Korea) was used for the measurement of cell viability in HK-2 cells after 24 hours of LPS treatment according to the manufacturer’s instructions. The optical densities of the samples were quantified at 450 nm using a microplate reader (Bio-Rad Laboratories, Hercules, CA, USA).

**Immunoblot analyses of HK-2 cells**

We conducted immunoblot analyses of HK-2 cell lysates as described previously [8]. The proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to nitrocellulose membranes, and incubated with antibodies against the following proteins: VDR (Santa Cruz Biotechnology); COX-2, Akt, pS473 Akt, pp65 NF-$\kappa$B and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Cell Signaling Technology, Beverly, MA, USA); EP4 and p65 NF-$\kappa$B...
The membranes were then incubated with horseradish peroxidase-conjugated anti-rabbit immunoglobulin G (IgG) or anti-mouse IgG (Invitrogen Biotechnology) and signal densities were detected and quantified using the ChemiDoc XRS Image system (Bio-Rad Laboratories).

**Fractionation of the cellular membrane and cytoplasm of HK-2 cells**

Fractionation of the cellular membrane and cytoplasm of HK-2 cells was performed using a Mem-PER Plus Membrane Protein Extraction kit (Thermo Scientific, Waltham, MA, USA) according to the manufacturer's protocol. HK-2 cells were washed with Cell Wash Solution, resuspended in permeabilization buffer, and incubated for 10 minutes with constant mixing at 4°C. The cytoplasmic supernatant was harvested after centrifugation at 16,000g for 15 minutes. The pellet was resuspended in solubilization buffer and the solubilized membrane fraction was harvested after centrifugation for 30 minutes at 4°C.

**Enzyme immunoassay**

HK-2 cells were homogenized by PRO-PREP™ Protein Extraction Solution (iNtRON Biotechnology, Seongnam, Korea) and then centrifuged for 10 minutes at 12,000g. Equal amounts of protein were analyzed by PGE2 enzyme-linked immunosorbent assay (ELISA) (Cayman Chemical, Ann Arbor, MI, USA) kit. The optical densities of the samples were quantified at 450 nm using a microplate reader (Bio-Rad Laboratories).

**TUNEL assay**

The number of apoptotic cells was counted in the HK-2 cells by terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) using a TUNEL Apoptosis Detection kit (Intergen, Purchase, NY, USA) following the manufacturer’s protocol. The immunofluorescence images for TUNEL assay were captured by confocal microscopy (LSM5 Live Configuration Variotwo VRGB; Zeiss, Oberkochen, Germany). The number of positive cells was quantified per high power field and at least 4–6 fields were analyzed for each slide.

**Immunoprecipitation for EP4**

HK-2 cells were lysed with kinase buffer (KB; 50 mM Tris-HCl [pH 7.4], 25 mM NaF, 40 mM β-glycerol phosphate [pH 7.4], 120 mM NaCl, 1% NP40) and then 1 mg of lysate was immunoprecipitated using 1 µg of anti-EP4 antibody (Santa Cruz Biotechnology) and protein G Sepharose 4 Fast Flow (GE Healthcare, Uppsala, Sweden). After washing with KB without 1% NP40, immunoblotting was performed with a PGE2 antibody (Biorbyt Ltd., Cambridge, UK).

**Real-time reverse transcription polymerase chain reaction of HK-2 cells**

Total RNA was isolated from HK-2 cells using a Nucleospin® RNA II kit (Macherey-Nagel, Düren, Germany). cDNA was synthesized using Reverse Transcriptase Premix (Elpis Biotech, Daejeon, Korea) and amplified in a Power SYBR® Green polymerase chain reaction (PCR) Master Mix (Applied Biosystems, Carlsbad, CA, USA) with gene-specific primer pairs (Table 1). The expres-

<table>
<thead>
<tr>
<th>Gene</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>hEP1</td>
<td>Fwd: TTGTGGATATCATGTTGGTG</td>
</tr>
<tr>
<td></td>
<td>Rev: ATGTACCCCAAAGGTCGAC</td>
</tr>
<tr>
<td>hEP2</td>
<td>Fwd: CCTGCTGTTGCCTTCTTGCT</td>
</tr>
<tr>
<td></td>
<td>Rev: GGCTTCGGGGCTGCT</td>
</tr>
<tr>
<td>hEP3</td>
<td>Fwd: AAGGCCACGCGCATCTGAT</td>
</tr>
<tr>
<td></td>
<td>Rev: AGCCGATATCCCATGATGAC</td>
</tr>
<tr>
<td>hEP4</td>
<td>Fwd: TCCGGCCTCAGCATTAC</td>
</tr>
<tr>
<td></td>
<td>Rev: GGCTGTGAAATAGGCAGTGGTA</td>
</tr>
<tr>
<td>hRANTES</td>
<td>Fwd: CTCGCTGCTATCCATTGCT</td>
</tr>
<tr>
<td></td>
<td>Rev: GGGTGTGGTTGCGAGAATA</td>
</tr>
<tr>
<td>hTNF-α</td>
<td>Fwd: GCCCCAGCAGCAGATC</td>
</tr>
<tr>
<td></td>
<td>Rev: AGCTGAGGTTGTGCTACAGAT</td>
</tr>
<tr>
<td>hIL-1β</td>
<td>Fwd: TGAAGCTGATGGCCCTACA</td>
</tr>
<tr>
<td></td>
<td>Rev: GTATGGTGTTGCGAGATTCGA</td>
</tr>
<tr>
<td>hMCP-1</td>
<td>Fwd: AGTGCTCAGAAAGCTGTTG</td>
</tr>
<tr>
<td></td>
<td>Rev: CCATGGAATCTCCGACCTTT</td>
</tr>
<tr>
<td>hGAPDH</td>
<td>Fwd: GAAAAACCTGCCAATAATGAGCA</td>
</tr>
<tr>
<td></td>
<td>Rev: TAGCCCGAGTATGCCCTTGA</td>
</tr>
</tbody>
</table>

EP, prostaglandin receptor; Fwd, forward; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; h, human; IFN-γ, interferon-γ; IL-1β, interleukin-1β; MCP, monocyte chemotactic protein; PCR, polymerase chain reaction; Rev, reverse; RANTES, regulated on activation, normal T cell expressed and secreted; TNF-α, tumor necrosis factor-α.
sion levels of mRNA were normalized to the expression of GAPDH. Quantitative real-time PCR was performed on an ABI 7500 FAST instrument (Applied Biosystems).

**Statistical analysis**

Data are expressed as the mean ± standard error of mean. Multiple comparisons were performed using one-way analysis of variance and Tukey’s post hoc test. All analyses were performed using SPSS software (ver. 20.0; IBM Corp., Armonk, NY, USA). A P < 0.05 was considered statistically significant.

**Results**

**Paricalcitol upregulates COX-2 and PGE₂ expression in LPS-exposed HK-2 cells**

Fig. 1 shows the effects of paricalcitol on VDR, COX-2, and PGE₂ in LPS-exposed HK-2 cells. Paricalcitol pretreatment significantly increased the expression of VDR and LPS exposure caused the suppression of VDR. Paricalcitol pretreatment largely restored the expression of VDR in LPS-exposed HK-2 cells (Fig. 1A). The expression of COX-2 was increased in paricalcitol-pretreated HK-2 cells and further enhanced in LPS-exposed cells treated with paricalcitol (Fig. 1B). HK-2 cells treated with paricalcitol produced a significantly higher level of PGE₂ than control cells. LPS exposure alone increased PGE₂ expres-

![Figure 1](image-url)
Figure 2. Paricalcitol activates PGE$_2$-EP4 signaling pathway in LPS-exposed HK-2 cells. (A) Paricalcitol increased the mRNA level of EP4 in LPS-exposed HK-2 cells, but did not affect mRNA expression of EP1–EP3 between groups. (B) The expression of EP4 protein determined by semiquantitative immunoblot analysis was significantly increased by paricalcitol in a dose-dependent manner compared to untreated control. (C) The cellular membrane fraction of EP4 protein expression was significantly increased in LPS-exposed HK-2 cells, and was further increased by paricalcitol. (D) Immunoprecipitation confirmed that the interactions between PGE$_2$ and EP4 was increased in LPS-exposed HK-2 cells and was further enhanced after paricalcitol pretreatment.

Cont, control; LPS, lipopolysaccharide; Pari, paricalcitol.

Each column represents the mean ± standard error of mean of three independent experiments. *$P < 0.05$ vs. Cont group; †$P < 0.05$ vs. Pari group; ‡$P < 0.05$ vs. LPS group.
sion than control cells and paricalcitol further enhanced PGE₂ expression in LPS-exposed cells (Fig. 1C).

**Paricalcitol activates the PGE₂-EP₄ signaling pathway in LPS-exposed HK-2 cells**

We examined the induction of PGE₂ receptor subtypes in paricalcitol-treated HK-2 cells. Paricalcitol significantly increased the mRNA level of EP₄ in HK-2 cells with or without LPS exposure. However, paricalcitol did not affect mRNA levels of EP1–EP3 (Fig. 2A). Paricalcitol increased the expression of EP4 protein dose-dependently, and the highest increase in EP4 expression was observed at 2 ng/mL paricalcitol (Fig. 2B). The cellular membrane/cytoplasm ratio of EP4 was further enhanced when paricalcitol-pretreated cells were exposed LPS injury (Fig. 2C). The interaction between PGE₂ and EP4 was investigated by immunoprecipitation. PGE₂/EP4 complex formation was increased after LPS exposure, and paricalcitol pretreatment further increased their interactions (Fig. 2D).

**Paricalcitol improves cell survival after LPS injury via EP₄**

The viability of cells treated with 0.5% NaHCO₃ was similar to that of control cells without any treatment ($P > 0.05$). LPS treatment decreased the cell viability to around 80% of the control group, and EP4 siRNA treatment further decreased the viability of LPS-exposed cells ($86.9 \pm 1.7$ vs. $81.7 \pm 1.1$; $P = 0.031$). Paricalcitol pretreatment significantly increased the viability of LPS-exposed cells, and this protective effect of paricalcitol was offset by AH-23848 cotreatment or an EP4 siRNA blockade (Fig. 3).

**EP₄ regulates the inhibitory effects of paricalcitol on p65 NF-κB activation**

LPS stimulation increased the phosphorylation of p65 NF-κB (Fig. 4A). Paricalcitol suppressed phosphorylation of p65 NF-κB, and the inhibitory effect of paricalcitol was reversed by AH-23848 cotreatment in LPS-exposed HK-2 cells. We further examined the subcellular localization of p65 NF-κB (Fig. 4B). p65 NF-κB was translocated to the nuclei in response to LPS stimulation. Paricalcitol decreased p65 NF-κB translocation, and cotreatment with AH-23848 and paricalcitol promoted the nuclear translocation of p65 NF-κB in LPS-exposed cells. To evaluate whether phosphorylation of p65 NF-κB was associated with the specific activation of EP4, we performed further

---

**Figure 3.** Paricalcitol protects HK-2 cells against endotoxin-induced death via an EP4-dependent pathway. Paricalcitol significantly prevented endotoxin-induced cell death. Co-treatment with (A) AH-23848, an EP4 antagonist or (B) EP4 siRNA restored the cell death to such an extent from LPS-exposed cells without paricalcitol. LPS, lipopolysaccharide; MTT assay, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay; siRNA, small interfering RNA. Each column represents the mean ± standard error of mean of three independent experiments. *$P < 0.05$. 

150 www.krcp-ksn.org
experiments for expression using EP4 siRNAs (Fig. 4C). As with AH-23848 treatment, EP4 siRNA enhanced the nuclear translocation of p65 NF-κB in LPS-stimulated cells treated with paricalcitol.

Figure 4. Paricalcitol inhibits p65 NF-κB activation after LPS treatment via an EP4-dependent pathway. p65 NF-κB phosphorylation and nuclear translocation was examined by semiquantitative immunoblot analysis. (A) Paricalcitol prevented phosphorylation of p65 NF-κB in LPS-treated cells. This inhibitory effect was reversed by AH-23848 co-treatment. *P < 0.05. (B) p65 NF-κB translocated to the nuclei in response to LPS stimulation. This translocation was suppressed by paricalcitol, whereas AH-23848 co-treatment blocked the suppressive effects of paricalcitol. *P < 0.05. (C) EP4-specific siRNA enhanced the nuclear translocation of NF-κB in LPS-exposed cells treated with paricalcitol. Cont, control; LPS, lipopolysaccharide; NF-κB, nuclear factor-κB; Pari, paricalcitol; siCont, control siRNA; siRNA, small interfering RNA. Each column represents the mean ± standard error of mean of three independent experiments. *P < 0.05 vs. Cont group; †P < 0.05 vs. LPS + siCont group; ‡P < 0.05 vs. LPS + Pari + siCont group.

The EP4-dependent pathway contributes to the inhibitory effects of paricalcitol on inflammatory cytokine production

We investigated mRNA levels of proinflammatory cytokines, such as regulated upon activation normal T cell expressed and secreted (RANTES), interleukin-1β (IL-1β),
monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-α (TNF-α). Induction of RANTES, IL-1β, MCP-1 and TNF-α mRNA was greater in LPS-exposed HK-2 cells than controls. Paricalcitol significantly reduced the production of these proinflammatory cytokines and EP4 siRNA largely reversed this decrease (Fig. 5).

**Paricalcitol increases phosphorylation of Akt via EP4 in LPS-exposed HK-2 cells**

Akt phosphorylation was significantly increased in response to endotoxin administration. Paricalcitol further enhanced the phosphorylation of Akt in LPS-exposed cells, whereas cotreatment with AH-23848 decreased phosphorylation of Akt (Fig. 6A). Similarly, EP4 siRNA significantly inhibited the phosphorylation of Akt in LPS-exposed cells treated with paricalcitol (Fig. 6B).

The EP4-dependent pathway contributes to the antiapoptotic effects of paricalcitol in LPS-exposed HK-2 cells

To evaluate the effect of paricalcitol on LPS-induced apoptosis, HK-2 cells stained with a TUNEL assay were analyzed after treatment with LPS with or without pari-

---

**Figure 5.** Paricalcitol suppresses the expression of inflammatory cytokines via an EP4-dependent pathway in LPS-exposed HK-2 cells. RT-PCR analysis showed that the mRNA levels of (A) RANTES, (B) IL-1β, (C) MCP-1 and (D) TNF-α were elevated in LPS-exposed HK-2 cells. Paricalcitol suppressed the LPS-induced overexpression of these inflammatory cytokines and EP4-specific siRNA ameliorated all of these suppressive effects.

Cont, control; IL-1β, interleukin-1β; LPS, lipopolysaccharide; MCP-1, monocyte chemoattractant protein-1; Pari, paricalcitol; RANTES, regulated upon activation normal T cell expressed and secreted; RT-PCR, real time polymerase chain reaction; siCont, control siRNA; siRNA, small interfering RNA; TNF-α, tumor necrosis factor-α.

*P < 0.05.
The degree of apoptosis was expressed as the number of TUNEL-positive cells (Fig. 7). LPS caused an increase in the number of apoptotic cells. Paricalcitol significantly decreased the number of TUNEL-positive cells, whereas EP4 siRNA increased the number of TUNEL-positive cells compared to that of LPS-exposed cells treated with paricalcitol alone.

Discussion

This study demonstrated that paricalcitol pretreatment had a protective effect against endotoxin damage in proximal tubular cells through the PGE₂–EP4-signaling pathway. The paricalcitol upregulated the cellular membrane expression of EP4 and increased PGE₂–EP4 binding. This EP4 activation attenuated HK-2 cell death on LPS exposure and induced the changes in its downstream signaling pathway including the phosphorylation of Akt and inactivation of p65 NF-κB and reduced several inflammatory cytokines and cell apoptosis. The protective effects of paricalcitol and changes in the EP4 downstream signal were definitely abolished with EP4 antagonist treatment or EP4–siRNA transfection. These findings suggest that paricalcitol improved inflammation and apoptosis of proximal tubular cells through activation of EP4 and its downstream signaling pathway.

LPS is a potent stimulant of inflammatory cell activation and evokes the secretion of proinflammatory mediators. PGE₂ is one of the representative mediators that are increased in immune cells and glomerular mesangial cells after LPS exposure and COX-2 is a major synthetic enzyme of PGE₂ [13,14]. In the present study, LPS stimulation increased the expression of COX-2 and PGE₂ production in HK-2 cells and paricalcitol pretreatment further increased their expression. We also found that paricalcitol treatment enhanced the cellular membrane expression of EP4 in LPS-exposed cells and that binding between PGE₂ and EP4 was enhanced in LPS-exposed paricalcitol-treated cells. These findings suggest that the responses of COX-2–PGE₂ pathway to LPS treatment in
HK-2 cells are similar to *in vitro* studies using different kinds of cell type and that paricalcitol reinforces the up-regulation of COX-2 and PGE2 signaling and their biological action.

In this study, we found that paricalcitol treatment increased the expression of EP4 mRNA, but the mRNA expression of *EP1-EP3* was not changed. These findings suggest that paricalcitol upregulates the PGE2 receptor EP4 more selectively. It was recently established that EP4 stimulation can activate the PI3K/Akt pathway, which results in the transcriptional activation of T-cell factor [15]. This activation increases the expression of COX-2, which leads to greater synthesis of PGE2. As a result, EP4 stimulation has the potential to set a positive feedback loop that would further stimulate its own receptor [16,17]. Therefore, we suggest that a positive feedback between COX-2 and EP4 might involve the EP4 selectivity of paricalcitol and that increased phosphorylation of Akt and greater interaction between PGE2 and EP4 support the concept of a positive feedback loop.

NF-κB is one of the important transcription factors initiating the inflammatory cascade and regulating the gene expression of cytokines, chemokines, and adhesion molecules [18]. Previous studies using various models of renal disease suggested that paricalcitol has inhibitory effects on NF-κB [7,8,19,20]. However, there were no previous studies to elucidate how paricalcitol regulates the NF-κB activity to prevent proximal tubule cell injury, especially in a model of sepsis-induced AKI. In the present study, we set inflammatory conditions in HK-2 cells using LPS stimulation, and our data indicated that paricalcitol pretreatment attenuates LPS-induced cell death that depends on the EP4 pathway and that EP4 controlled the inhibitory effect of paricalcitol on NF-κB phosphorylation and nuclear translocation. To determine the functional role of EP4 with paricalcitol effects further, EP4 siRNA
was used to investigate the effect on TNF-α, RANTES, MCP-1 and IL-1β, which was transcriptionally activated by NF-κB. As expected, paricalcitol obviously suppressed these proinflammatory cytokines in an EP4-dependent manner. These findings suggest that the EP4-dependent pathway is one of the major anti-inflammatory mechanisms of paricalcitol in endotoxin-induced tubular cell injury.

PI3K is a main target of PGE₂–EP4 signaling, and its activation subsequently increases the phosphorylation of Akt kinase [11]. The phosphorylation of Akt is a representative signal that leads to antiapoptotic effects and cell survival via upregulation of several downstream kinases [12,21,22]. In the present study, paricalcitol increased the phosphorylation of Akt in LPS-treated cells and an EP4 blockade reversed the phosphorylation of Akt. In addition, a TUNEL assay showed that apoptotic cell death from LPS treatment was significantly attenuated in paricalcitol-treated cells via the EP4-dependent pathway. These findings suggest that the antiapoptotic effect through an EP4-specific pathway is a critical protective mechanism of paricalcitol in LPS-exposed HK-2 cells.

Paricalcitol significantly increased VDR expression in the present study. It seems reasonable, but raises the interesting questions why paricalcitol, VDR activator, increases the amount of VDR protein and whether beneficial effects of EP4 activation is associated VDR upregulation. While this experiment did not show clear mechanism on this result, we presume that paricalcitol may activate the positive loop, which involves the increment in protein level of VDR [23]. Moreover, paricalcitol-induced caspase inhibition may increase the VDR expression, because the activation of caspase-3 enhances VDR cleavages [24,25]. In addition, we suggest that VDR upregulation potentially mediated the EP4 activation. The EP4 promoter includes nucleotide sequences of vitamin D response element, which potentially binds VDR and activates EP4 signaling pathway [26–28].

Vitamin D deficiency has a close relationship to the adverse outcomes of sepsis, including increased length of hospitalization, sepsis-induced AKI, and mortality [29–31]. Paricalcitol has been widely used in various diseases with few adverse reactions and good tolerance. Our study suggests that paricalcitol may have potential as a therapeutic intervention for septic AKI via the EP4-dependent pathway. However, the limitation of our experimental design was that paricalcitol was applied prior to the LPS injury and there is insufficient in vivo evidence. In addition, this study also had a limitation to demonstrate the EP4 own role in LPS-injured cells. Further in vivo experiments and clinical studies to investigate the therapeutic role of EP4 activation are needed.

In conclusion, our study suggested that paricalcitol up-regulated EP4 expression in HK-2 cells after LPS injury, and the subsequent activation of the EP4 pathway mediated activation of Akt and inhibition of NF-κB. These actions of paricalcitol on PGE₂–EP4-signaling pathway contributed to its anti-inflammatory and antiapoptotic properties in LPS injury. Therefore, paricalcitol treatment provides a new therapeutic strategy for sepsis-induced AKI through activation of PGE₂–EP4 receptor signaling.

**Conflicts of interest**

All authors have no conflicts of interest to declare.

**Acknowledgments**

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2015R1A1A1A05001599), and Clinical Research Institute grant (CMCDJ-A-2015-007) funded by The Catholic University of Korea Daejeon St. Mary’s Hospital. The authors also wish to acknowledge the financial support of the Korean Society Nephrology (Chong Kun Dang, 2016).

**References**


[29] Ko EJ, Kim BH, Jeong HY, Soe SU, Yang DH, Lee SY: Serum 25-hydroxyvitamin D as a predictor of hospitalization-free
